

Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



21 December 2018.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.
Scrip Name: SUNPHARMA

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Name: 524715

Dear Sirs,

Sub: Receipt of US FDA Approval of ELEPSIA™ XR 1000mg and ELEPSIA™ XR 1500mg

Dear Sir/Madam,

We are pleased to inform you that the U.S. Food and Drug Administration (USFDA) has granted approval for the New Drug Application (NDA), to a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (SPIL), for Elepsia™ XR 1000 mg (levetiracetam 1000 mg) and Elepsia™ XR 1500 mg (levetiracetam 1500 mg). This product was filed from SPIL's Halol (Gujarat, India) facility.

SPIL's wholly owned subsidiary had in-licensed ELEPSIA™ XR from Sun Pharma Advanced Research Company Ltd. (SPARC) in July 2016.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

A handwritten signature in blue ink, appearing to read "A. I. Bhuta".

Ashok I. Bhuta
Compliance Officer

Encl: as above